Sverige -
svenska -
Läkemedelsverket (Medical Products Agency)
attentin 20 mg tablett
orifarm ab - dexamfetaminsulfat - tablett - 20 mg - isomalt hjälpämne; dexamfetaminsulfat 20 mg aktiv substans
Sverige -
svenska -
Läkemedelsverket (Medical Products Agency)
attentin 20 mg tablett
medartuum ab - dexamfetaminsulfat - tablett - 20 mg - dexamfetaminsulfat 20 mg aktiv substans; isomalt hjälpämne
Sverige -
svenska -
Läkemedelsverket (Medical Products Agency)
erlotinib orion 100 mg filmdragerad tablett
orion corporation - erlotinibhydroklorid - filmdragerad tablett - 100 mg - erlotinibhydroklorid 109,3 mg aktiv substans; laktos (vattenfri) hjälpämne
Sverige -
svenska -
Läkemedelsverket (Medical Products Agency)
erlotinib orion 25 mg filmdragerad tablett
orion corporation - erlotinibhydroklorid - filmdragerad tablett - 25 mg - erlotinibhydroklorid 27,3 mg aktiv substans; laktos (vattenfri) hjälpämne
Sverige -
svenska -
Läkemedelsverket (Medical Products Agency)
erlotinib orion 150 mg filmdragerad tablett
orion corporation - erlotinibhydroklorid - filmdragerad tablett - 150 mg - laktos (vattenfri) hjälpämne; erlotinibhydroklorid 163,9 mg aktiv substans
Sverige -
svenska -
Läkemedelsverket (Medical Products Agency)
sorafenib bluefish 200 mg filmdragerad tablett
bluefish pharmaceuticals ab - sorafenibtosilat - filmdragerad tablett - 200 mg - sorafenibtosilat 274 mg aktiv substans; natriumlaurilsulfat hjälpämne
Europeiska unionen -
svenska -
EMA (European Medicines Agency)
sutent
pfizer limited - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - antineoplastiska medel - gastrointestinal stromal tumour (gist)sutent is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib mesilate treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sutent is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sutent is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours with disease progression in adults. experience with sutent as first-line treatment is limited (see section 5.
Europeiska unionen -
svenska -
EMA (European Medicines Agency)
retsevmo
eli lilly nederland b.v. - selpercatinib - carcinoma, non-small-cell lung; thyroid neoplasms - antineoplastiska medel - retsevmo as monotherapy is indicated for the treatment of adults and adolescents 12 years and older with advanced ret-mutant medullary thyroid cancer (mtc)advanced ret fusion-positive non-small cell lung cancer (nsclc) not previously treated with a ret inhibitoradvanced ret fusion-positive thyroid cancer who require systematic therapy following prior treatment.
Europeiska unionen -
svenska -
EMA (European Medicines Agency)
sunitinib accord
accord healthcare s.l.u. - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - antineoplastiska medel - gastrointestinal stromal tumour (gist)sunitinib accord is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sunitinib accord is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sunitinib accord is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours (pnet) with disease progression in adults.
Sverige -
svenska -
Läkemedelsverket (Medical Products Agency)
suprefact depot 9,45 mg implantat
paranova läkemedel ab - buserelinacetat - implantat - 9,45 mg - buserelinacetat 9,9 mg aktiv substans - buserelin